UFR de Physique

Propositions de stages en laboratoire -- M2

Les offres sont actualisées en mai. Par exemple, les offres de stages pour l'année universitaire 2015-2016 seront mises en place en mai 2015, les offres de stages pour l'année universitaire 2016-2017 seront mises en place pour en mai 2016, etc.

Microfluidics for the biomechanical cytometry of Leukemia cells and their physical modeling

  • Option Finalisée « Physicien des hopitaux » du parcours Physique Biologique et Médicale
  • Laboratoire: Autre (Autre)
  • Responsable du stage: Dominique Collard (collard@iis.u-tokyo.ac.jp, 06 26 49 09 04)
  • Co-responsable(s): Dr. Cagatay Tarhan, Dr. Ryohei UENO, Dr. Thierry IDZIOREK (Ce stage se fait a l'IRCL/SMMIL-E)
  • Mots clés: MEMS technology, cell biomechanics, Leukemia, biophysical phenotyping and cytometry

Acute myeloid leukemia is a highly heterogeneous disease. Our consortium already demonstrated that persistent leukemia cells are few, sometimes less than few hundreds. These cells are (i) the causative agents of late relapse, (ii) refractory to treatments and (iii) leading to relapsing patients poor survival. Deep sequencing by NGS allows identification of these residual cells but their detection is still technically challenging due to lack of phenotypic markers. There is a critical need to find new ways to detect and purify them to anticipate relapse. . This master subject aims to analyse small subpopulation of leukemic cells through their biomechanical properties using microfluidic technologies. A microfluidic device will be designed and processed to identify (count) the blast cells in a cell culture sample. The microfluidic device will stimulate the biomechanical response of a cell by squeezing it in a microchannel. The cell size, deformability or recovery time will be measured by recording electric signals on integrated electrodes in contact with fluid as impedance of a flowing cell alters the measured fluid conductivity. The microfluidic device will be evaluated by detecting and counting blast cells from prepared solutions before using it on actual samples. Evaluations will be carried out with an in-house mouse model of tumour dormancy using the fluorescent-protein-tagged cell lines with the objective of technology/protocol transfer to the clinics.